Literature DB >> 17419714

Immune activation suppresses initiation of lytic Epstein-Barr virus infection.

Kristin Ladell1, Marcus Dorner, Ludwig Zauner, Christoph Berger, Franziska Zucol, Michele Bernasconi, Felix K Niggli, Roberto F Speck, David Nadal.   

Abstract

Primary infection with Epstein-Barr virus (EBV) is asymptomatic in children with immature immune systems but may manifest as infectious mononucleosis, a vigorous immune activation, in adolescents or adults with mature immune systems. Infectious mononucleosis and chronic immune activation are linked to increased risk for EBV-associated lymphoma. Here we show that EBV initiates progressive lytic infection by expression of BZLF-1 and the late lytic genes gp85 and gp350/220 in cord blood mononuclear cells (CBMC) but not in peripheral blood mononuclear cells (PBMC) from EBV-naive adults after EBV infection ex vivo. Lower levels of proinflammatory cytokines in CBMC, used to model a state of minimal immune activation and immature immunity, than in PBMC were associated with lytic EBV infection. Triggering the innate immunity specifically via Toll-like receptor-9 of B cells substantially suppressed BZLF-1 mRNA expression in acute EBV infection ex vivo and in anti-IgG-stimulated chronically latently EBV-infected Akata Burkitt lymphoma cells. This was mediated in part by IL-12 and IFN-gamma. These results identify immune activation as critical factor for the suppression of initiation of lytic EBV infection. We hypothesize that immune activation contributes to EBV-associated lymphomagenesis by suppressing lytic EBV and in turn promotes latent EBV with transformation potential.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17419714     DOI: 10.1111/j.1462-5822.2007.00937.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  15 in total

1.  Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production.

Authors:  Marcus Dorner; Simone Brandt; Marianne Tinguely; Franziska Zucol; Jean-Pierre Bourquin; Ludwig Zauner; Christoph Berger; Michele Bernasconi; Roberto F Speck; David Nadal
Journal:  Immunology       Date:  2009-12       Impact factor: 7.397

2.  Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus.

Authors:  Stefanie Iskra; Markus Kalla; Henri-Jacques Delecluse; Wolfgang Hammerschmidt; Andreas Moosmann
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

3.  Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay.

Authors:  Vahid Younesi; Forough Golsaz Shirazi; Ali Memarian; Amir Amanzadeh; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  Cytotechnology       Date:  2013-02-13       Impact factor: 2.058

4.  Activation of NF-κB via endosomal Toll-like receptor 7 (TLR7) or TLR9 suppresses murine herpesvirus 68 reactivation.

Authors:  Florian Haas; Kazuma Yamauchi; Monika Murat; Michele Bernasconi; Noboru Yamanaka; Roberto F Speck; David Nadal
Journal:  J Virol       Date:  2014-06-18       Impact factor: 5.103

5.  Distinct ex vivo susceptibility of B-cell subsets to epstein-barr virus infection according to differentiation status and tissue origin.

Authors:  Marcus Dorner; Franziska Zucol; Christoph Berger; Rahel Byland; Gregory T Melroe; Michele Bernasconi; Roberto F Speck; David Nadal
Journal:  J Virol       Date:  2008-03-05       Impact factor: 5.103

6.  Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection.

Authors:  Markus P Rechsteiner; Christoph Berger; Ludwig Zauner; Jürg A Sigrist; Matthias Weber; Richard Longnecker; Michele Bernasconi; David Nadal
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

7.  TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism.

Authors:  J Noack; M Jordi; L Zauner; D Alessi; A Burch; M Tinguely; M Hersberger; M Bernasconi; D Nadal
Journal:  Cell Death Dis       Date:  2012-06-21       Impact factor: 8.469

Review 8.  Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection.

Authors:  Maria R Petrara; Riccardo Freguja; Ketty Gianesin; Marisa Zanchetta; Anita De Rossi
Journal:  Front Microbiol       Date:  2013-10-18       Impact factor: 5.640

9.  Telomerase activity impacts on Epstein-Barr virus infection of AGS cells.

Authors:  Jürgen Rac; Florian Haas; Andrina Schumacher; Jaap M Middeldorp; Henri-Jacques Delecluse; Roberto F Speck; Michele Bernasconi; David Nadal
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

10.  Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells.

Authors:  Ada Funaro; Giorgio Gribaudo; Anna Luganini; Erika Ortolan; Nicola Lo Buono; Elisa Vicenzi; Luca Cassetta; Santo Landolfo; Richard Buick; Luca Falciola; Marianne Murphy; Gianni Garotta; Fabio Malavasi
Journal:  BMC Biotechnol       Date:  2008-11-12       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.